Navigation Links
Avantra Biosciences teams with TGen Drug Development to assist pharma

SCOTTSDALE, Ariz. Feb. 1, 2011 Avantra Biosciences (Avantra) today announced the selection of TGen Drug Development (TD2) as a key test site for Avantra's new biomarker quantitation platform.

Avantra, based near Boston in Woburn, Mass., has created an automated multiplex immunoassay system to evaluate the associations between elevated protein levels, unique patient characteristics, and drug responses. The new Q400 Biomarker Workstation and innovative Angio Qx BioChip Immunoassay will enable the rapid measurement of biomarkers that can predict how cancer patients will respond to new drug therapies.

Combined with TD2's integrated suite of molecular analysis tools designed to reduce the uncertainty in the drug development process the partnership with Avantra will help enable emerging drug companies to quickly and safely get their discoveries to market, where they can benefit patients.

"Avantra's advanced testing technologies will help scientists speed development of their laboratory discoveries into new therapeutics in a safe and cost-effective manner," said TD2 President Dr. Stephen Gately. "Early identification of biomarkers that are associated with drug activity will facilitate a more seamless translation to measure the most appropriate markers for the same drug in the clinic."

TD2, based in Scottsdale, Ariz., provides drug development firms with expertise in moving promising laboratory discoveries through the pre-clinical, clinical and regulatory approval steps of getting new drugs to patients as quickly and safely as possible.

Avantra will assist in this process with the commercialization of the new Q400 BioMarker Workstation and the Angio Qx BioChip Immunoassay. The power and simplicity of Avantra's QPDx platform offers researchers easy-to-use bench-top multiplex protein tests that deliver rapid quantitative results with very little setup time. The completely self-contained Q400/Angio Qx combination provides quantitative protein biomarker results for ten analytes in less than an hour, with less than five minutes of sample preparation.

Avantra is currently developing additional assays for its QDPxTM Product Line that will target specific areas in cancer medicine.

"TD2 is a leader and change agent in the scientific community's effort to apply innovative molecular analysis technologies to solve challenges in the drug development and oncology fields," said Brian McKernan, CEO of Avantra.

"We are delighted to partner with TD2. Our collaboration with their outstanding team of professionals is a critical component to Avantra's goal of integrating our QPDx proteomic solutions with novel and cutting edge molecular profiling technologies," McKernan said. "We anticipate our collaboration with TD2 will enable Avantra to expedite the release of new oncology focused QPDx BioChip panels, and enable TD2 to couple advanced multiplex protein technologies with their innovative drug profiling platform."


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related biology news :

1. Human cells can copy not only DNA, but also RNA, says team from Pitt, Helicos BioSciences
2. InQ Biosciences Introduces First Fully Integrated Cell Research System
3. Energy Biosciences Institue named "Deal of Distinction" by tech-transfer group
4. Fire forecast technology could help rescue teams save lives
5. In the test tube, teams reconstruct a cancer cells beginning
6. White House Science Fair showcases Lemelson-MIT InvenTeams
7. Energy drinks may give young sports teams an edge, study says
8. LSU expert teams with Ohio State researcher to track species affected by Gulf oil spill
9. EPA awards more than $1 million to college teams for environmental innovation
10. CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions
11. The PTR Group Announces Financial and Technical Support to US FIRST Robotics Competition Teams
Post Your Comments:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... -- Connected health pioneer, Joseph C. Kvedar , MD, ... and wellness, and the business opportunities that arise from ... of Healthy Things . Long before health and ... Kvedar, vice president, Connected Health, Partners HealthCare, was creating ... from the hospital or doctor,s office into the day-to-day ...
(Date:10/27/2015)... Calif. , Oct. 27, 2015 Synaptics Inc. ... solutions, today announced that Google has adopted the Synaptics ... touch controller solutions to power its newest flagship smartphones, ... by Huawei. --> ... like Google to provide strategic collaboration in the joint ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... an additional independent director, and the Company welcomes ... allegations in a recent anonymous internet report on NW ... initiatives. Linda Powers stated, "We agree ...
(Date:11/27/2015)... , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... announced today that it has closed the sale of ... to Guerbet (GBT- NYSE Euronext) in a transaction valued ... four manufacturing facilities and a total of approximately 1,000 ... the St. Louis area. This ...
(Date:11/26/2015)... England , November 26, 2015 ... innovative medical device company specializing in imaging technologies, announced today ... European Commission as part of the Horizon 2020 European Union ... carry out a large-scale clinical trial in breast cancer. ... (Logo: , --> --> ...
(Date:11/25/2015)... , November 25, 2015 ... cat and human plaque and pave the way for more ... problems in cats     --> ... most commonly diagnosed health problems in cats, yet relatively little ... now. Two collaborative studies have been conducted by researchers from ...
Breaking Biology Technology: